Compare Ecolab Inc. (ECL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Incyte Corporation — how do they compare? Ecolab Inc. trades at $281.36 (market cap $78.97B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: Ecolab Inc. is far larger — about 3.5× Incyte Corporation's market cap, and Ecolab Inc. pays a 1.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Incyte Corporation for 33 Days on average.
| ECL | INCY | |
|---|---|---|
Market Cap | $78.97B | $22.85B |
Volume | 974,947 | 1,927,029 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $129.93 |
52-Week Low | $245.73 | $83.80 |
Typical Hold Time | 90 Days | 33 Days |
Enterprise Value | $87.75B | $18.35B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported $16.08B in 2025 revenue, with a net income margin of 12.57% and strong profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook remains positive with a consensus price target of $326.38, implying 17% upside, supported by analyst buy ratings (78%). Risks include elevated valuation multiples and increased debt from the CoolIT acquisition. Earnings growth in high-tech and digital segments is a key catalyst, though cost fluctuations pose headwinds.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
